AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04339985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 OINTMENT vehicle
Description: ATx201 OINTMENT vehicle
Study NCT02821741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Twin Stim Plus, 3rd Edition
Description: Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
Study NCT01478009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Description: Korean red ginseng(3.0g/day) for 12 weeks
Study NCT01478009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3.0g/day) for 12 weeks
Study NCT02821741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Twin Stim Plus, 3rd Edition
Description: Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
Study NCT02821741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medoc Pathway System
Description: Device used to apply Thermal stimulation to both arms.
Study NCT00464451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Study NCT00464451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral hydrate
Description: Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Study NCT04141631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)
Description: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value
Study NCT02821741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medoc Pathway System
Description: Device used to apply Thermal stimulation to both arms.
Study NCT04470544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Given PO
Study NCT04470544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: At Investigator discretion
Study NCT02544113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Treatment with thymoglobulin and delayed CNI post OLT
Study NCT02544113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal transplant immunosuppression
Study NCT02262364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APS
Description: See above
Study NCT04066400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Dietary Counselling
Study NCT04066400 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Intervention
Description: Dietary Counselling
Study NCT00572351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Wine
Description: 8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
Study NCT00572351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Wine
Description: 8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
Study NCT03218826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT03218826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03218826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03218826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3Kbeta Inhibitor AZD8186
Description: Given PO
Study NCT02666378 — intervention group
Intervention type: OTHER
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Description: Subjects will be recruited for observational cardiac magnetic resonance imaging.
Study NCT02666378 — intervention group
Intervention type: OTHER
Intervention: Echocardiogram (ECHO)
Description: Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
Study NCT01928966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pumpkin Seeds
Description: Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
Study NCT03830190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson's disease nurse specialist care
Description: Specialized nursing care provided by a Parkinson's disease nurse specialist
Study NCT00264979 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Simultaneous surgery
Description: Simultaneous surgery of colorectal cancer and synchronous liver metastases
Study NCT00264979 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sequential surgery
Description: Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
Study NCT03642938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
Study NCT03498378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (IV on days 1 and 15 of 28 day cycle)
Study NCT03498378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day.
Study NCT03498378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min.
Study NCT03642938 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The Control group will perform 30 minutes of quiet rest.
Study NCT01934803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc gluconate
Description: Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
Study NCT01934803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03035890 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
Study NCT03035890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-Therapeutic Agent
Description: Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity.
Study NCT00757913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: n-3 enriched nutrition
Study NCT01502618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: N/A. Protocol is the focus group
Study NCT06072222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks
Study NCT06072222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks
Study NCT06072222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
Study NCT06072222 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilator
Description: ventilator
Study NCT06072222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator
Description: ventilator
Study NCT00049036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00049036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00049036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00049036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01694784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
Study NCT01694784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Study NCT03724903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ductal lavage
Description: The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
Study NCT01694784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Study NCT01694784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framed Information Sheet
Description: Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Study NCT03730285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Installation of videotelephone with broadband in patient's home
Study NCT04000620 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: treatment intent surgery
Study NCT04000620 — intervention group
Intervention type: PROCEDURE
Intervention: punture
Description: diagnostic punture
Study NCT01646190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Carbohydrate load
Description: oral intake in the evening before surgery and 2-3h before intubation
Study NCT01646190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individualized i.v fluids therapy
Description: by Transoesophageal aortic US-Doppler done intraoperatively
Study NCT01646190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting state after midnight
Description: No preoperative glucose load
Study NCT01646190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Nasogastric tube postoperatively
Description: Withdrawal after complete awakening in operating room
Study NCT01646190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: urinary catheter removal
Description: at POD 1
Study NCT01646190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral liquids
Description: 0.3-0.5L oral liquids at 6h postoperatively on POD 0
Study NCT01646190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation of inspirex utilization
Description: using 6-8 times/day to prevent pulmonary atelectasis
Study NCT01646190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), >4h out of bed on POD1, >6h on POD2, complete at POD3
Study NCT01646190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preanesthetic medication
Description: Preanesthetic oral medication before surgery
Study NCT00049036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00049036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00049036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03513497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized acrylic mouthguard
Description: Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
Study NCT01164943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with human FSH
Description: Human FSH
Study NCT01164943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with recombinant FSH
Description: Recombinant FSH
Study NCT03724903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid therapy
Description: Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
Study NCT02989246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator protocol
Description: Open loop ventilator management by a computer based protocol
Study NCT02989246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Catheter
Description: Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
Study NCT01080118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq
Description: Subjects were taught with the Airtraq video laryngoscope
Study NCT01080118 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group, taught with a standard Macintosh laryngoscope
Description: Subjects were taught how to use the Mackintosh blade first
Study NCT00419848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Cap 100mg- 100mg/daily
Study NCT00419848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
Study NCT05410405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant site preparation
Description: piezoelectric bone surgery osseodensification drills
Study NCT02800967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pure Aronia juice
Description: Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
Study NCT02800967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia juice-based beverage
Description: Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
Study NCT02527252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy
Study NCT02800967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
Study NCT04334239 — intervention group
Intervention type: OTHER
Intervention: Oncological certification
Description: Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
Study NCT00229957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Study NCT01960985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physicaltherapy
Study NCT03551197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and formoterol bid
Description: At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
Study NCT01837719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300-mg capsule
Study NCT00229957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT00229957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management
Study NCT03852849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal involved intervention strategies
Description: Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
Study NCT03852849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The dosage of 400mg EFV
Description: The dosage of 400mg EFV will be used in the antiviral therapy.
Study NCT02527252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Massage
Study NCT02661269 — intervention group
Intervention type: DEVICE
Intervention: Videomicroscopy of the sublingual microcirculation
Description: Measuring total vessel density with the Cytocam-IDF camera.
Study NCT02661269 — intervention group
Intervention type: DEVICE
Intervention: Bio-impedance measurements.
Description: measuring resistance and reactance with the BIVA method.